Four IL-23 inhibitors, namely ustekinumab, tildrakizumab, guselkumab, and risankizumab, have received approval for the treatment of psoriasis and psoriatic arthritis (83, 84). This evidence concerns the gene IL23A and psoriatic arthritis.